NHS trust apologises after patients wrongly given chemotherapy for years

NHS trust apologises after patients wrongly given chemotherapy for years

Leaders at University Hospitals Coventry and Warwickshire NHS Trust have apologised for “failures” that led to patients wrongly being given chemotherapy for years.

Patients with brain tumours were severely harmed, some were misdiagnosed and others were told if they stopped chemotherapy they would die, despite this not being true.

Professor Andy Hardy, who is chief executive, and trust chair Sue Noyes, said in a statement that meaningful action has been taken to address the concerns detailed in a Royal College of Physicians (RCP) report, published on Wednesday.

The trust asked the RCP to conduct a review after doctors at the trust raised the alarm over patients cared for by a consultant who retired.

“We are deeply sorry to all the patients and families affected by failures within our neuro-oncology service under the care of retired clinical oncologist Ian Brown,” Prof Hardy and Ms Noyes said in a statement.

“We recognise the concern, distress and loss of trust experienced by those who placed their faith in us during some of the most difficult moments of their lives.”

The statement said the RCP report showed how patients’ chemotherapy treatment “was prolonged beyond accepted national guidance, and that opportunities were missed to challenge and oversee these clinical decisions sooner.

“It also, distressingly, shows that some patients experienced harm because of the care they received.

“This is far below the standards our patients deserve and that we expect. We let you down, and for that we offer our sincere apologies.”

The pair said the trust has extended its historical review back to 2005, when national guidance for chemotherapy drug temozolomide (TMZ) was first published, “to ensure affected patients are identified and supported”.

The statement added the trust has already taken “decisive steps to strengthen our clinical governance and ensure all treatment decisions are made collaboratively”.

An independent review of “speaking up processes” are also being independently reviewed “to ensure staff feel fully supported and confident in raising any concerns.”

The trust said anyone currently receiving cancer treatment at the trust can be reassured it is “safe, effective, and closely monitored and our expert cancer teams are here for you whenever you need us”.

A doctor who worked with Prof Brown, Mr N, has retired from the trust, it said.

It has made a formal regulatory referral regarding Mr N to the Nursing and Midwifery Council (NMC) regulator.

All living patients receiving TMZ at the trust have already had their care re-reviewed internally to ensure it aligned with expected standards, the trust added.

A “comprehensive independent external clinical review process” will also evaluate all living patients who received over 12 cycles of TMZ under Prof Brown.

The trust added: “We have initiated discussions with the NHS England regional director of patient safety to establish clear requirements and methodology for reviewing the cohort of deceased patients who received non-standard chemotherapy regime.”

Published: by Radio NewsHub
Start your relationship

If you are interested in receiving bulletins from Radio News Hub or would simply like to find out more please fill in the form below. We operate on annual contracts - spread the cost is available.

We aim to get back to you within 48 hours